NeOnc Technologies (NTHI) vs Retension Pharmaceuticals (RTSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NeOnc Technologies is the larger company by market cap ($90.9 million vs $87.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | RTSN |
|---|---|---|
| Share price | $3.15 | $10.51 |
| Market cap | $90.88M | $87.57M |
| 1-day change | -9.48% | -19.22% |
| YTD return | -61.91% | — |
| 1-year return | -46.25% | — |
| EPS (TTM) | $-1.95 | $-2.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $39.99K | — |
| Revenue growth (YoY) | -51.82% | — |
| Net income (latest FY) | $-62.15M | — |
| Operating margin | -145637.52% | — |
| Net margin | -155404.38% | — |
| 52-week high | $11.38 | $18.64 |
| 52-week low | $2.50 | $9.23 |
| Distance from 52-week high | -72.31% | -43.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +439.68% | +391.63% |
| Average volume | 187.23K | 144.93K |
| Shares outstanding | 28.85M | 8.33M |
| Employees | 5 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Retension Pharmaceuticals
RTSN stock →Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
NTHI vs RTSN FAQ
Which is bigger, NeOnc Technologies or Retension Pharmaceuticals?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $90.88M compared with $87.57M for Retension Pharmaceuticals (RTSN).
Are NeOnc Technologies and Retension Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.